Vicore Pharma Holding AB
STO:VICO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.9665
23.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vicore Pharma Holding AB
Gross Profit
Vicore Pharma Holding AB
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Vicore Pharma Holding AB
STO:VICO
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Biogaia AB
STO:BIOG B
|
Gross Profit
kr950.2m
|
CAGR 3-Years
20%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
||
Bonesupport Holding AB
STO:BONEX
|
Gross Profit
kr752.8m
|
CAGR 3-Years
60%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
||
Vitrolife AB
STO:VITR
|
Gross Profit
kr2.1B
|
CAGR 3-Years
27%
|
CAGR 5-Years
18%
|
CAGR 10-Years
20%
|
||
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Gross Profit
kr20B
|
CAGR 3-Years
19%
|
CAGR 5-Years
17%
|
CAGR 10-Years
30%
|
||
BioArctic AB
STO:BIOA B
|
Gross Profit
kr565.1m
|
CAGR 3-Years
144%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
Vicore Pharma Holding AB
Glance View
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.